Key result
Inactivated coxsackievirus A16 vaccine provides ~100% cross-protection against lethal clinical strains in gerbils.
Absolute Event Rate: 100% vs 0%
Does not support clinical use; extends preclinical cross-protection data for CVA16 vaccines.
(gerbils) after two doses of intraperitoneal inoculation. One week after the booster immunization, the geometric mean titres of the neutralizing antibodies for the 10246, 40812TXT, 11203SD, TJ-224 and CA16-194 strains from different regions of China were 137.8, 97.8, 113.4, 64.1 and 122.3, respectively. A CVA16 vaccine dose above 25 U was also able to provide 100% cross-protection against lethal challenges with these five clinical strains in gerbils. Immunization at a one-week interval could maintain a high level of neutralizing antibody titres for at least 8 weeks. Thus, the vaccine produced by this CVA16-393 strain might be promising.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied Coxsackievirus A16 (CVA16) infection. Inactivated coxsackievirus A16 vaccine (CVA16-393 strain) vs. PBS with aluminum hydroxide adjuvant was evaluated on Survival rate after lethal challenge with CVA16 strains. An inactivated coxsackievirus A16 vaccine produced from the CVA16-393 strain provided 100% cross-protection against lethal challenges with five clinical strains in gerbils at doses above 25 U.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: